Celularity Inc.
Investor
Relations
Corporate Profile
Celularity, headquartered in Florham Park, NJ, is a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Latest Press Releases
Events & Presentations
Celularity Investor Presentation
Last Updated May, 2022
Celularity AML Program Update Webcast
December 17, 2021 at 11:00AM
Celularity at Oppenheimer 32nd Annual Healthcare Conference
March 17, 2022 at 11:20AM
Celularity at Oppenheimer 32nd Annual Healthcare Conference
March 17, 2022 at 11:20AM
Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference